IP Library Granted Patent US 8,992,471
Granted Patent B2
US 8,992,471 · App. 12/740,890 · Granted Mar 31, 2015

Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity

Inventors: Tammy R. Dugas (Bossier City, LA); Alok Khandelwal (Shreveport, LA); James John Kleinedler, III (Shreveport, LA); John Devlin Foley (Lino Lakes, MN)
Assignees: Nanocopoeia, Inc.; Louisiana State University Health Sciences Center Office of Research
A61L31/16A61L31/10A61L31/146A61F2/915A61F2002/91508A61F2002/91558A61F2250/0067A61L2300/608A61L2300/416A61L2300/422
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,992,471
App. No.
12/740,890
Granted
Mar 31, 2015
Kind
B2
Abstract

The present invention relates generally to the maintenance of blow flood using drug eluting stents and/or other coated medical devices to increased length of time of blood flow. Further, the present invention relates to drug-releasing coated devices for reducing smooth muscle cell proliferation and platelet activity to further limit restenosis utilizing resveratrol and quercetin, polyphenols that are linked to the cardioprotection of red wine consumption. The present invention also provides products and methods for treating or preventing atherosclerosis, stenosis, restenosis, smooth muscle cell proliferation, platelet cell activation and other clotting mechanisms, occlusive disease, or other abnormal lumenal cellular proliferation condition in a location within the body of a patient.

Claims (19)

1. An implantable medical device, comprising:

an expandable balloon catheter having an outer surface; and

an adherent layer on the balloon catheter comprising a composite of polymer and a first active agent selected from a group consisting of resveratrol, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable derivatives thereof, and a second active agent selected from a group consisting of quercetin, pharmaceutically acceptable salts thereof, and pharmaceutically acceptable derivatives thereof, wherein the first and second active agents are dispersed within the polymer,

wherein a concentration of the first active agent based on a surface area of the balloon catheter ranges from about 1 to about 5 μg/mm 2 , and a concentration of the second active agent based on the surface area of the balloon catheter ranges from about 1 to about 5 μg/mm 2 ,

and further wherein the composite includes a plurality of layers.

2. The device of claim 1 , wherein the polymer is biodegradable.

3. The device of claim 1 , wherein the polymer is a bioabsorbable polymer.

4. The device of claim 1 wherein the polymer is selected from a group consisting of polystyrene-polyisobutylene block copolymers, polyethylene terephthalate, poly(lactide), poly(lactide-co-glycolide), poly(caprolactone), poly(lactide-co-caprolactone), poly-(hydroxybutyrate/hydroxyvalerate) copolymer, poly(vinylpyrrolidone), polytetrafluoroethylene, poly(2-hydroxyethylmethacrylate), poly(n-butyl methacrylate), poly(ethylene-co-vinyl acetate), poly(vinylidene fluoride-co-hexafluoropropene), poly(etherurethane urea), silicones, acrylics, epoxides, polyesters, polyurethanes, desaminotyrosine polyarylate, parylenes [polyxylylenes], polyphosphazene polymers, fluoropolymers, polyamides, isoolefin homopolymers and copolymers, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, methacrylate homopolymers and copolymers, polyethers, polyesters, polycarbonates and copolymers, polyethylene oxides, poly(ethylene glycol) and derivatives, carbo-films, self-assembling polymer films and liposomes cellulosics, chondroitin-sulfate, gelatin, amino acid-based polymers, fibrin, chitin, extracellular matrix proteins, heparinized coatings, phospholipid liposomes and self-assembled arrays, poly-lactides and mixtures thereof.

5. The device according to claim 1 , wherein the first active agent is resveratrol and the second active agent is quercetin, and further wherein a ratio of a weight of resveratrol to a weight of quercetin is in a range selected from a group consisting of about 1:5, about 1:2, and about 1:1.

6. The device according to claim 1 , wherein a weight of the first active agent and a weight of the second active agent are in a ratio which is selected from a group consisting of about 1:1, about 1:2, about 2:1, about 1:2.5, about 2.5:1, about 1:4, about 4:1, about 1:5, about 5:1, about 1:10, about 10:1, about 1:20, about 20:1, about 1:25, about 25:1, about 1:50, about 50:1, about 1:100, about 100:1, about 1:200, about 200:1, about 1:250, about 250:1, about 1:500, and about 500:1.

7. The device according to claim 1 , wherein

a first weight comprises a weight of the first and second active agents; and

a second weight comprises a weight of the polymer; and

the first weight and the second weight are in a ratio of the first and second active agents to the polymer is in a range selected from a group consisting of about 1:1, about 1:2, about 2:1, about 1:2.5, about 2.5:1, about 1:4, about 4:1, about 1:5, about 5:1, about 1:10, about 10:1, about 1:20, about 20:1, about 1:25, about 25:1, about 1:50, about 50:1, about 1:100, about 100:1, about 1:200, about 200:1, about 1:250, about 250:1, about 1:500, and about 500:1.

8. The device according to claim 7 , wherein the ratio is varied in some of the layers.

9. The device of claim 1 , wherein each of the active agents may have different release profiles.

10. The device of claim 1 , wherein a release profile of the active agents may be selected between rapid and delayed.

11. The device of claim 1 , wherein a rapid profile coating releases at least one of the active agents substantially within one to a few hours.

12. The device of claim 1 , wherein a delayed profile coating releases at least one of the active agents over a period of at least one month, at least two months, at least six months, or at least one year.

Assignments (8)
CHANGE OF NAME Recorded Apr 9, 2025
From: PXMMI, LLC
To: FLEX PHARMA, LLC
Reel/Frame 070792/0850 →
NUNC PRO TUNC ASSIGNMENT Recorded Apr 8, 2025
From: NANOCOPOEIA, LLC
To: PXMMI, LLC
Reel/Frame 070766/0704 →
AFFIDAVIT RE: ASSGNMENT FOR THE BENEFIT OF CREDITORS (MINNESOTA STATE COURT FILE NO. 62-CV-24-5879) Recorded Mar 11, 2025
From: NANOCOPOEIA, LLC
To: LIGHTHOUSE MANAGEMENT GROUP, INC.
Reel/Frame 070542/0880 →
AFFIDAVIT RE: ASSGNMENT FOR THE BENEFIT OF CREDITORS (MINNESOTA STATE COURT FILE NO. 62-CV-24-5879) Recorded Mar 11, 2025
From: LIGHTHOUSE MANAGEMENT GROUP, INC.
To: NANOCOPOEIA, LLC
Reel/Frame 070735/0519 →
CHANGE OF ADDRESS Recorded Sep 14, 2021
From: NANOCOPOEIA, LLC
To: NANOCOPOEIA, LLC
Reel/Frame 057500/0557 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2017
From: NANOCOPOEIA, INC.
To: NANOCOPOEIA, LLC.
Reel/Frame 043792/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2010
From: DUGAS, TAMMY R.; KHANDELWAL, ALOK; KLEINEDLER, JAMES JOHN, III
To: LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER OFFICE OF RESEARCH
Reel/Frame 024888/0835 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2010
From: FOLEY, JOHN DEVLIN
To: NANOCOPOEIA, INC.
Reel/Frame 024888/0885 →
Continuity (2)
Provisional Application 61001916 · Nov 5, 2007
Related Publication 20100331965A1 · Dec 30, 2010